Audit 404910

FY End
2025-12-31
Total Expended
$9.21M
Findings
0
Programs
1
Year: 2025 Accepted: 2026-06-25
Auditor: RSM US LLP

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.103 FOOD AND DRUG ADMINISTRATION RESEARCH $3.06M Yes 0

Contacts

Name Title Type
EBVDJ7R7AY35 Stephanie Rizk Auditee
2028281600 Jeri Fleming Auditor
No contacts on file

Notes to SEFA

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of Medical Device Innovation Consortium (the Organization) under programs of the federal government for the year ended December 31, 2025. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of the Organization, it is not intended to and does not present the financial position, changes in net assets, or cash flows of the Organization.
Expenses reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement.
Indirect costs allocated to awards for the year ended December 31, 2025, were based on a rate negotiated with the Organization’s cognizant federal agency, the Department of Health and Human Services. The Organization does not utilize the de minimis indirect cost rate per CFR 200.414.